Home - Business - Marathon Pharmaceuticals Launched ZiNGO To Reduce Anxiety

Marathon Pharmaceuticals Launched ZiNGO To Reduce Anxiety

Posted on September 11, 2018 in Business Education News Public Education

Marathon Pharmaceuticals develops and launches rare disease treatments. Marathon’s focus is on small volume medications that are difficult to manufacture. The company also explores treatments for neurological disorders, rare cancers, and various other conditions. Its headquarters is in Northbrook, Illinois and there are offices in Chicago and New Jersey. The company is opening the Marathon Bioscience Center for clinical, regulatory, and research staff. They develop therapies for central nervous system diseases, cancer, endocrine deficiencies, gastrointestinal diseases, and movement disorders.

One of the medications they specialize in is Amytal Sodium. It is a barbiturate derivative used to treat insomnia. Marathon Pharmaceuticals also markets Seconal Sodium for insomnia, as well as a pre-anesthetic prior to surgery. It markets PEPCID, a prescription strength histamine H2-receptor antagonist. It decreases the amount of acid in the stomach. Patients have had fast heart burn relief and the alleviation of nighttime heartburn. It is recommended by doctors as a short-term ulcer treatment and a gastroesophageal treatment. Marathon marketed opium tincture for the treatment of diarrhea. It reduces muscle contractions and digestive secretions.

ZiNGO, a powder intradermal injection system, is the company’s most well-known product. It delivers local anesthetic for venous access pain without a needle. It is a single-use, hand-held device that doesn’t need to be refrigerated. It delivers .5mg of powdered licodaine with the push of a button. It numbs the application site in under three minutes, and the powder diminishes 10 minutes later. An IV cannulation involves placing a cannula inside a vein, which causes children to have anxiety. ZiNGO guarantees that children wont feel any pain due to the powered lidocaine. MD, William T. Zempsky, led ZiNGO’s pediatric clinical trials. One of the most common causes of procedural-related pain at the hospital is peripheral intravenous catheter placement.

Marathon Pharmaceuticals has partnered with Medline to market and distribute ZiNGO. Luke Stevens is the President of Medline’s Nutrition and Pharmaceuticals Division. He said his company was excited to work with Marathon Pharmaceuticals and provide this innovative product. ZiNGO was originally provided to children’s hospitals, community hospitals, and medical centers.